Amendments to the Claims/Listing of Claims

Please amend claim 14 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Original) A method of inducing differentiation of mammary epithelial cells, the method comprising administering an effective amount of galanin or a functional analog or agonist thereof to the mammary epithelial cells.

2. (Original) A method of inducing differentiation of mammary epithelial cells in a mammal, the method comprising increasing the level of galanin or a functional analogor agonist thereof in the mammary tissue of the mammal.

3. (Original) A method of increasing milk production in a mammal, the method comprising increasing the level of galanin or a functional analog or agonist thereof in the mammary tissue of the mammal.

4. (Original) A method as claimed in claim 2 or claim 3, wherein the level of galanin is increased by administering to a mammal an amount of galanin or a functional analog or agonist thereof effective to induce differentiation of mammary epithelial cells and/or increase milk production in the mammal.

5. (Original) A method as claimed in any one of claims 1 to 4, wherein the galanin analog is a polypeptide comprising the following fragment: GWTLNSAGYLLGP (SEQ ID NO : 1).

6. (Original) A method as claimed in any one of claims 1 to 4, wherein the galanin is a human galanin polypeptide having the following amino acid sequence: GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS (SEQ ID NO : 2) or a functional equivalent thereof or a functional fragment thereof.

13. (Original) A method as claimed in any one of claims 1 to 4, wherein the galanin analog is a rat GALP (1-60) polypeptide having the following amino acid sequence: APAHRGRGGWTLNSAGYLLGPVLHLSSKANGGRKTDSALEILDLWKAIDGLR YSRSPRMT

(SEQ ID NO : 13) or a functional equivalent thereof or a functional fragment thereof.

14. (Currently Amended) A method as claimed in any one of claims 1 to 4, wherein the galanin analog is selected from the group consisting of :
(i) Galanin-(2-29) (i. e. deletion of first amino acid);
(ii) Galanin-(3-29) (i. e. deletion of first 2 amino acids);
(iii)Galanin- (l-15) (i. e.deletion of amino acids 16-29/30) ;
(iv)Galanin- (1-16) (ie. deletion of amino acids17-29/30) ;
(v) M40:galanin- (1-13)-Pro-Pro-Ala-Leu-Ala-Leu-Ala-amide **(SEQ ID NO: 30)**;
(vi)M15 (galantide): Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO: **[[13]] 31**);
(vii) M35: galanin (1-13) -bradykinin (2-9) amide;
(viii) M32: galanin(1-13)-neuropeptide Y (25-36) amide; and
(ix) C7: galanin(1-13)-spantide amide.

15. (Original) A method as claimed in any one of claims 1 to 4, wherein the galanin analog is an agonist of theGalR2 receptor.

16. (Original) A method as claimed in claim 15, wherein the agonist of theGalR2 receptor is a GALP (1-60) polypeptide or galanin (2-16).

17. (Original) A method as claimed in any one of claims 1 to 3, wherein the level of galanin in the mammary tissue is increased by administering to the mammal an amount of estrogen or a functional analog thereof effective to increase expression of galanin in the mammal.